Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00714961 · ClinicalTrials.gov registry record · Phase 3
Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,491
- Enrollment target
NCT00714961: Completed Phase 3 study, sponsored by Sanofi.
NCT00714961 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 3,491 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (352% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00714961, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,491 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of aspirin plus clopidogrel is more effective than aspirin alone in preventing another heart attack, chest pain, stroke or death in people who have already had a heart attack that was treated with fibrinolytic therapy.
Interventions
- DRUG Placebo
- DRUG Clopidogrel (SR25990)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,491 participants |
| Start Date | 2003-02 |
| Est. Completion | 2005-01 |
| Phase | Phase 3 |
What the finished NCT00714961 record still lists
NCT00714961 is an interventional study that assigns participants to a tested intervention. Its 3,491 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (352% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00714961 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00714961 about?
NCT00714961 is a clinical study titled "Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction". The purpose of this study is to determine if the combination of aspirin plus clopidogrel is more effective than aspirin alone in preventing another heart attack, chest pain, stroke or death in people who have already had a heart attack that was treated with fibrinolytic therapy.
What is the current status of trial NCT00714961?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,491 participants. The study started on 2003-02. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00714961?
The interventions under investigation include: Placebo (DRUG), Clopidogrel (SR25990) (DRUG).
Who is sponsoring clinical trial NCT00714961?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00714961's enrollment target sits among peer trials
3,491 70th of 2000 higher than 1,931 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia